On July 12th, Nie Qiuhua, former president of Ningbo University, Ruan Liemin, secretary of the Party Committee of the First Affiliated Hospital of Ningbo University, Hu Baohua, director of the Alumni Office of Ningbo University, and clinical research expert He Wenming visited Tianyuan Biotechnology for exchange and discussion on the work of jointly building the Ningbo University Biomedical Innovation Research Institute. Chairman Huang Bisheng and CEO Zhu Pengcheng met with visitors. The responsible persons and experts of Sicheng Biotechnology and Youbao Youbao Medical Laboratory under Tianyuan Biotechnology attended the conference for exchange.

Chairman Huang Bisheng warmly welcomes the visit of Ningda and its affiliated First Hospital delegation. He pointed out that under the guidance of the implementation of the "Medical Peak" plan by the Ningbo Municipal Party Committee and Government, in order to assist the construction of the "Double First Class" of his alma mater Ningbo University and promote the innovative development of the medical department of Ningbo University, as an alumni enterprise, he is willing to contribute his modest efforts to the development of his alma mater. At the same time, in order to fully leverage the respective advantages and resources of the school and enterprise, actively carry out industry university research cooperation, and jointly build the "Ningbo University Biomedical Innovation Research Institute". Emphasize that the enterprise will fully support the joint construction work of Ningbo University Biomedical Innovation Research Institute, and jointly promote deep cooperation between industry, academia, research and application in the field of biomedical innovation.

During the discussion and exchange session, both parties exchanged speeches on strengthening resource integration, promoting deep cooperation, implementing the joint construction agreement, and advancing the construction of the Biomedical Innovation Research Institute.

CEO Zhu Pengcheng gave a special report on the joint construction of the "Ningbo University Biomedical Innovation Research Institute" project. Ningbo University, based on the forefront of local academia and industry, has strong comprehensive strength and will have more advantages in clinical diagnosis and treatment. Zhejiang Tianyuan Biotechnology Co., Ltd. was founded by alumni enterprise Zhejiang Tianhao Holdings Co., Ltd., and jointly established the first metabolic immune monitoring joint laboratory in China with the National Health Commission's research institute. With immunological testing, gene testing, and cell therapy as technological breakthroughs, it achieves early diagnosis, early treatment, and early recovery. Developing genetic testing reagents using ctDNA methylation technology to screen for early cancer. Developing metabolic immune reagents using metabolites and immune cells to evaluate immune health. Establish a stem cell bank, matching bank, cancer cell bank, tumor infiltrating immune cell bank, etc. Realize precise cell anti-tumor treatment and achieve rapid immune recovery through nutritional intervention. By formulating immune assessment standards, immune testing, and immune intervention, effective monitoring of the entire immune process can be achieved, achieving immune protection and health protection. Two GMP biological laboratories with a total area of 3500 square meters have been established in Ningbo to support research and production. Both parties will deepen cooperation within the framework of the joint construction agreement, focus on key areas and specific projects, solidly promote the construction of the Biomedical Innovation Research Institute, and jointly create a new situation of digital biomedical innovation industry education integration, collaborative innovation, and common development.

Liu Guangcheng, a postdoctoral fellow in biology at Hirosaki University in Japan, gave a lecture on clinical research and drug development of stem cells, the development of the tumor infiltrating lymphocyte (TIL) therapy cell market, and clinical treatment. He also provided a comprehensive introduction to the construction of the HLA typing library for umbilical cord placenta amniotic mesenchymal stem cells in enterprises, as well as the innovative technological advantages, clinical cases, and industrial layout of TIL cells. Hu Yongwu, a postdoctoral fellow in genetics at Harvard University in the United States, and Wang Zhigang, a Ph.D. in immunology at Tianyuan Biotechnology, had in-depth communication and exchanges with Nanjing University and its affiliated First Hospital on genetic testing.

President Nie and Secretary Ruan of Ningbo University and its affiliated First Hospital expressed strong support for the establishment of the Ningbo University Biomedical Innovation Research Institute, fully affirmed the work of Tianyuan Biotechnology in the field of biology, and hoped to jointly build the Biomedical Innovation Research Institute through school enterprise cooperation, carry out industry university research cooperation around enterprise needs, accelerate the medical clinical transformation and application of enterprises, and jointly create a first-class biomedical cutting-edge technology transformation platform in the province.

Finally, the attendees unanimously agreed that this cooperation is an important opportunity to promote the high-quality development of industry, academia, research and application in the context of the current implementation of the "Medical Summit" plan in Ningbo City. Both sides exchanged ideas and suggestions on the joint construction of the Biomedical Innovation Research Institute. According to the agreement, both parties will leverage their respective resources and professional advantages, establish a high-level research and innovation team based on the research institute, carry out research and sustainable talent training programs for biopharmaceutical innovation, promote the industrialization of biopharmaceutical innovation technology achievements, and jointly build an innovative ecosystem for biopharmaceutical industry services. This has profound significance for promoting the strategy of "co construction and sharing, national health" proposed in the "Healthy China 2030 Plan Outline".